Korean J Schizophr Res.  2020 Oct;23(2):45-50. 10.16946/kjsr.2020.23.2.45.

Treatment-Resistant Schizophrenia: Terminology and Clinical Features

• Lee K

• KMID: 2508351
• DOI: http://doi.org/10.16946/kjsr.2020.23.2.45

Abstract

Schizophrenia is one of serious mental illnesses and is often described as a heterogeneous disorder. Approximately one-third of schizophrenia cases are treatment-resistant schizophrenia (TRS). The aim of this study was to review the definitions and clinical features of TRS. Though it was found that the criteria for TRS were considerably diverse, the Treatment Response and Resistance in Psychosis (TRRIP) consensus criteria were recently introduced. According to the TRRIP criteria, TRS should be suspected if symptoms persist alongside psychotic symptoms despite sufficient treatment for ≥12 weeks, or two or more symptoms persist significantly for ≥6 weeks. The clinical characteristics of TRS includes an earlier age of onset, more severe and familial form, possibly more rural residence, unlikely association with male sex, and an increase in cognitive deficits.

Keyword

Clinical feature; Clozapine; Compliance; Schizophrenia; Treatment-resistance; 임상양상; 조현병; 치료순응도; 치료저항성; 클로자핀

Reference

1. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005; 2:e141.

2. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988; 45:789–796.

3. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992; 49:538–544.

4. Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull. 1993; 19:287–302.

5. Kinon BJ, Kane JM, Johns C, Perovich R, Ismi M, Koreen A, et al. Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull. 1993; 29:309–314.

6. Barnes TR, McEvedy CJ. Pharmacological treatment strategies in the non-responsive schizophrenic patient. Int Clin Psychopharmacol. 1996; 11 Suppl 2:67–71.

7. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of partients with schizophrenia, second edition. Am J Psychiatry. 2004; 161:1–56.

8. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz W, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012; 13:318–378.

9. National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. London: National Institute for Health and Care Excellence;2014.

10. Lee JS, Yun JY, Kang SH, Lee SJ, Choi JH, Nam B, et al. Korean Medication Algorithm for Schizophrenia 2019, second revision: treatment of psychotic symptoms. Clin Psychopharmacol Neurosci. 2020; 18:386–394.

11. Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017; 174:216–229.

12. Elkis H. Treatment-resistant schizophrenia. Psychiatr Clin North Am. 2007; 30:511–533.

13. Essock SM, Hargreaves WA, Covell NH, Goethe J. Clozapine’s effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull. 1996; 32:683–697.

14. Lieberman JA. Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia. J Clin Psychiatry. 1999; 60 Suppl 12:9–12.

15. Lindenmayer JP. Treatment refractory schizophrenia. Psychiatr Q. 2000; 71:373–384.

16. Thorup A, Waltoft BL, Pedersen CB, Mortensen PB, Nordentoft M. Young males have a higher risk of developing schizophrenia: a Danish register study. Psychol Med. 2007; 37:479–484.

17. Meltzer HY, Rabinowitz J, Lee MA, Cola PA, Ranjan R, Findling RL, et al. Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Am J Psychiatry. 1997; 154:475–482.

18. Teo C, Borlido C, Kennedy JL, De Luca V. The role of ethnicity in treatment refractory schizophrenia. Compr Psychiatry. 2013; 54:167–172.

19. Wimberley T, Stovring H, Sorensen HJ, Horsdal HT, MacCabe JH, Gasse C. Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. Lancet Psychiatry. 2016; 3:358–366.

20. Povlsen UJ, Norrng U, Fog R, Gerlach J. Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand. 1985; 71:176–185.

21. Kuha S, Miettinen E. Long-term effect of clozapine in schizophrenia a retrospective study of 108 chronic schizophrenics treated with clozapine for up to 7 years. Nord Psykiatr Tidsskr. 1986; 40:225–230.

22. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl). 1989; 99 Suppl:S18–S27.

23. Vassos E, Pedersen CB, Murray RM, Collier DA, Lewis CM. Meta-analysis of the association of urbanicity with schizophrenia. Schizophr Bull. 2012; 38:1118–1123.

24. Ripke S, O’Dushlaine C, Chambert K, Moran JL, Kahler AK, Akterin S, et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet. 2013; 45:1150–1159.

25. Joober R, Rouleau GA, Lal S, Bloom D, Lalonde P, Labelle A, et al. Increased prevalence of schizophrenia spectrum disorders in relatives of neuroleptic-nonresponsive schizophrenic patients. Schizophr Res. 2005; 77:35–41.

26. Kinon BJ. The Group of Treatment Resistant Schizophrenias. Heterogeneity in treatment resistant schizophrenia (TRS). Front Psychiatry. 2018; 9:757.

27. Iasevoli F, Giordano S, Balletta R, Latte G, Formato MV, Prinzivalli E, et al. Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones. Prog Neuropsychopharmacol Biol Psychiatry. 2016; 65:34–48.

28. Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol. 2014; 29:63–76.

29. Schennach R, Riedel M, Musil R, Moller HJ. Treatment Response in First-episode Schizophrenia. Clin Psychopharmacol Neurosci. 2012; 10:78–87.

30. Hollis C. Adult outcomes of child- and adolescent-onset schizophrenia: diagnostic stability and predictive validity. Am J Psychiatry. 2000; 157:1652–1659.

31. Reichert A, Kreiker S, Mehler-Wex C, Warnke A. The psychopathological and psychosocial outcome of early-onset schizophrenia: preliminary data of a 13-year follow-up. Child Adolesc Psychiatry Ment Health. 2008; 2:6.

32. Kayo M, Tassell I, Hiroce V, Menezes A, Elkis H. Does lack of improvement in the first two weeks predict treatment resistance in recent-onset psychosis? Clinics. 2012; 67:1479–1482.

33. Joober R, Rouleau GA, Lal S, Dixon M, O’Driscoll G, Palmour R, et al. Neuropsychological impairments in neuroleptic-responder vs. -nonresponder schizophrenic patients and healthy volunteers. Schizophr Res. 2002; 53:229–238.

34. de Bartolomeis A, Balletta R, Giordano S, Buonaguro EF, Latte G, Iasevoli F. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses. Psychiatry Res. 2013; 210:387–395.

35. Frydecka D, Beszlej JA, Goscimski P, Kiejna A, Misiak B. Profiling cognitive impairment in treatment-resistant schizophrenia patients. Psychiatry Res. 2016; 235:133–138.

36. Hippius H. A historical perspective of clozapine. J Clin Psychiatry. 1999; 60 Suppl 12:22–23.

37. Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry. 2007; 18:39–60.

38. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry. 2001; 158:518–526.

39. Üçok A, Çikrikçili U, Karabulut S, Salaj A, Öztürk M, Tabak Ö, et al. Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia. Int Clin Psychopharmacol. 2015; 30:290–295.

40. Mouaffak F, Tranulis C, Gourevitch R, Poirier MF, Douki S, Olié JP, et al. Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. Clin Neuropharmacol. 2006; 29:28–33.

41. Samanaite R, Gillespie A, Sendt KV, McQueen G, MacCabe JH, Egerton A. Biological predictors of clozapine response: a systematic review. Front Psychiatry. 2018; 9:327.

42. Okhuijsen-Pfeifer C, Sterk A, Horn I, Terstappen J, Kahn R, Luykx J. Demographic and clinical features as predictors of clozapine response in patients with schizophrenia spectrum disorders: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2020; 111:246–252.

43. Maccall C, Billcliff N, Igbrude W, Natynczuk S, Spencer E, Flanagan R. Clozapine: more than 900 mg/day may be needed. J Psychopharmacol. 2009; 23:206–210.